In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
Bruce the dog reviews cultivated meat
In Scotland, Philip Lymbery, a journalist writing for The Scotsman has turned to his beloved pup Bruce to review Chick Bites dog treats, the...
Breaking nugget news: Japanese scientists create lab-growth chicken with circulatory system
In Tokyo, researchers have created the world’s largest, and most advanced, lab-growth chicken nugget.
Featuring “veins” that deliver nutrients and oxygen, the new nugget...
Be green on the green with biodegradable golf balls
In Vancouver, a company is selling golf balls that biodegrade in two weeks and are made from compressed corn starch, calcium carbonate, glycerin, and...